ArticleBrain and behavior2026
Real-World Clinical Outcomes and Corticosteroid Tapering in Telitacicept-Based Therapy for Ocular Myasthenia Gravis: An Exploratory Analysis by Prior Treatment History.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionOcular myasthenia gravis (OMG) is an autoantibody-mediated disease characterized by extraocular muscle weakness. Telitacicept has shown potential in treating autoimmune diseases, but its efficacy and corticosteroid-tapering outcomes in OMG remain unexamined.
methodsThis retrospective, multicenter study evaluated the efficacy and corticosteroid-tapering outcomes of telitacicept in 19 OMG patients (11 with refractory OMG and eight with newly/reinitiated treatment OMG). The primary endpoint was the proportion of patients achieving minimal symptom expression (MSE) within 6 months. Secondary endpoints included changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores and reductions in daily prednisone dosage, cumulative response rate (CRR), and short-term tolerability.
resultsFollowing 6 months of telitacicept treatment, 68.42% of the overall cohort achieved MSE, with the median MG-ADL score significantly decreasing from 3.00 to 0.00 (p < 0.0001). Daily prednisone dosage substantially decreased: the median daily prednisone dose fell from 20.00 to 5.00 mg (p < 0.0001), and 84.21% of patients received prednisone at ≤5 mg/day at month 6. All patients met the predefined initial response criterion within 5 weeks. The refractory and newly/reinitiated treatment groups achieved final MSE rates of 72.7% and 62.5%, respectively, and both groups showed significant reductions in prednisone dependence. This cohort had no serious adverse events.
conclusionIn this exploratory cohort, telitacicept-based therapy may represent a promising option for OMG, with favorable clinical outcomes, substantial prednisone dose reduction, and acceptable short-term tolerability in patients with different prior treatment histories. Further prospective controlled studies are warranted.
Indexed as
Identifiers
42850995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.